After the FDA rejection of Zurzuvae in one type of depression, and the triple failure of neuro asset dalzanemdor, Sage was ...

Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Investing.com -- Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm slashed its price target for the stock to $180 from $250 ...

Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.

Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pipeline re-prioritization underway while signaling that the formerly restrained company is ready to make some deals. “I ...

Biogen announced a reprioritization of resources regarding its pipeline of therapeutics to address Alzheimer’s disease, deciding to discontinue development of Aduhelm and choosing to advance ...

Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030. Challenges like ...